Aim: The aim of this work was the evaluation of the usefulness of 124I PET/CT sequential scans to predict absorbed doses to metastatic thyroid cancer in patients undergoing 131I therapy.
Methods: From July 2011 until April 2012 8 patients affected by metastatic thyroid cancer were enrolled. Each patient underwent 4 PET/CT scans at 4, 24, 48, 72 h after the administration of about 74 MBq of 124I. Blood samples and whole body exposure measurements were obtained to calculate blood and red marrow doses. Activity concentrations and lesion volumes obtained from PET/CT images were used to evaluate tumour doses with MIRD formalism and spheres model. The average administered 131I therapeutic activity was 6475 MBq (range: 3700-9250 MBq).
Results: 124I PET/CT images showed, with a very good resolution, all 131I avid lesions detected by post therapy whole body scans. The average dose rates for blood, red marrow and lesions were respectively: 6.58E-02 ± 1.64E-02 mGy/MBq, 5.73E-02 ± 1.57E-02 mGy/MBq, 2.22E+01 ± 1.62E+01 mGy/MBq. Three out of eight patients did not show any uptake of 124I in all PET/CT scans, despite high level of TSH and CT detectable lesions. Post-therapy 131I whole body scan confirmed the absence of focal iodine uptake.
Conclusion: Negative 124I PET/CT images probably could be used as predictive of real absence of iodine avidity, avoiding all toxicity from useless 131I therapy. A higher number of patients is necessary to validate these preliminary results and a project is ongoing to compare MIRD results to voxel dosimetry based on Monte Carlo simulation.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A Method for Validating PET and SPECT Cameras for Quantitative Clinical Imaging Trials Using Novel Radionuclides.
J Nucl Med
January 2025
Department of Nuclear Medicine, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
Our aim is to report methodology that has been developed to calibrate and verify PET and SPECT quantitative image accuracy and quality assurance for use with nonstandard radionuclides, especially with longer half-lives, in clinical imaging trials. Procedures have been developed for quantitative PET and SPECT image calibration for use in clinical trials. The protocol uses a 3-step approach: check quantitative accuracy with a previously calibrated radionuclide in a simple geometry, check the novel trial radionuclide in the same geometry, and check the novel radionuclide in a more challenging, complex geometry (the National Electrical Manufacturers Association [NEMA] NU-2 International Electrotechnical Commission [IEC] image-quality phantom).
View Article and Find Full Text PDF[18F]Tetrafluoroborate: a new NIS PET/CT radiopharmaceutical. An overview focused on differentiated thyroid cancer.
Eur Thyroid J
January 2025
G Treglia, Repubblica e Cantone Ticino Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Background: In relapsing differentiated thyroid cancer (DTC), the in vivo evaluation of natrium-iodine symporter (NIS) expression is pivotal in the therapeutic planning and is achieved by [131/123I]Iodine whole-body scan. However, these approaches have low sensitivity due to the low sensitivity due to the low resolution of SPECT. [18F]Tetrafluoroborate (TFB) has been proposed as a viable alternative, which could outperform [131/123I]Iodine scans owing to the superior PET resolution.
View Article and Find Full Text PDF[F]TFB PET/CT misses intense [I]iodine-avid metastases after redifferentiation therapy in metastatic thyroid cancer.
EJNMMI Res
October 2024
Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, P.O. Box 77, New York, NY, 10065, USA.
Article Synopsis
- The study investigates the effectiveness of Fluorine 18-labelled tetrafluoroborate ([F]TFB) as an imaging alternative to iodine for assessing metastatic thyroid cancer and potential radioiodine treatment success.
- Five patients participated in the research, receiving both [F]TFB and iodine imaging on the same day. Results showed that [F]TFB identified 58% of lesions compared to 91% for iodine imaging, indicating its lower sensitivity.
- The conclusion drawn highlights that [F]TFB did not successfully predict iodine uptake in patients undergoing redifferentiation therapy, raising questions about its reliability for other treatment cases or in untreated patients.
Construction and preclinical evaluation of a I-labelled bispecific antibody targeting PD-L1 and PD-L2.
Eur J Nucl Med Mol Imaging
December 2024
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Peking University, No. 52 Fu-Cheng Rd, Beijing, 100142, People's Republic of China.
Article Synopsis
- The study focused on developing a bispecific antibody, NB12, that targets PD-L1 and PD-L2, aimed at monitoring cancer patient responses to immune checkpoint inhibitors (ICI) through a radiotracer called [I]I-NB12.
- In vitro testing showed that [I]I-NB12 had a high affinity for its targets, was effectively taken up by certain cancer cells, and demonstrated favorable pharmacokinetics.
- Micro-PET/CT imaging indicated that [I]I-NB12 successfully accumulated in tumor regions, confirming its potential for dynamic imaging in cancer diagnostics.
Theranostic Intratumoral Convection-Enhanced Delivery of I-Omburtamab in Patients with Diffuse Intrinsic Pontine Glioma: Pharmacokinetics and Lesion Dosimetry.
J Nucl Med
September 2024
Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, New York; and.
Diffuse intrinsic pontine glioma (DIPG) is a rare childhood malignancy with poor prognosis. There are no effective treatment options other than external beam therapy. We conducted a pilot, first-in-human study using I-omburtamab imaging and theranostics as a therapeutic approach using a localized convection-enhanced delivery (CED) technique for administering radiolabeled antibody.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!